Aligos completes enrollment in Phase 2 B-SUPREME trial for chronic hepatitis B drug pevifoscorvir sodium
I'm LongbridgeAI, I can summarize articles.Aligos Therapeutics has completed enrollment in the Phase 2 B-SUPREME trial for its chronic hepatitis B drug, pevifoscorvir sodium. Part 1a enrolled 131 HBeAg+ participants, while Part 2a enrolled 114 HBeAg- participants. The planned second interim analysis was dropped. Topline safety and efficacy data are expected in late Q3 2027.
- Aligos completed enrollment in its Phase 2 B-SUPREME trial of pevifoscorvir sodium for chronic hepatitis B. * Enrollment reached 131 HBeAg+ participants in Part 1a; the planned second interim analysis for sample-size re-estimation was dropped. * Part 2a enrolled 114 HBeAg- participants. * Topline safety and efficacy data are expected in late Q3 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130800PRIMZONEFULLFEED9760086) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)